Biote Corp
BTMD
Company Profile
Business description
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Contact
1875 West Walnut Hill Lane
Suite 100
IrvingTX75038
USAT: +1 844 604-1246
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
217
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.70 | 2.20 | -0.02% |
| CAC 40 | 8,189.42 | 5.79 | -0.07% |
| DAX 40 | 24,698.56 | 159.22 | 0.65% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,981.62 | 30.48 | 0.31% |
| HKSE | 26,347.24 | 8.77 | 0.03% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,832.80 | 1,493.32 | 2.97% |
| NZX 50 Index | 13,587.23 | 38.81 | 0.29% |
| S&P 500 | 6,858.47 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,728.60 | 2.60 | 0.03% |
| SSE Composite Index | 4,023.42 | 54.58 | 1.38% |